Use of Erandsneha in Viral Infection in COVID 19

Abstract

The pandemic outbreak of coronavirus disease 2019 (COVID-19) caused significant morbidity and mortality, finally led to an emergency of major international concern.[i] The virus has created an unfavourable socioeconomic impact globally. The initial clusters of cases were reported in December 2019 at Wuhan. The current testimonies indicate that SARS-CoV-2 spread to humans through transmission from wild animals illegally sold in the Huanan Seafood Wholesale Market[ii]. On January 7, 2020, the causative agent was identified as a new coronavirus (2019-nCoV), and the disease was later named as COVID-19 by the WHO.[iii] Compared with other viral diseases, the hallmark of the novel coronavirus is the wide range of disease severity experienced by the patients. Only a minority of COVID-19 patients require hospitalization, the effects of infection for these people are dramatic, in some life threatening cases. Infection with SARS-CoV-2 causes severe pneumonia, intermittent fever, and cough. Symptoms of rhinorrhea, pharyngitis, and sneezing have been less commonly observed. Patients often develop acute respiratory distress syndrome within two days of hospital admission, requiring ventilatory support. It has been observed that during this phase, the mortality tends to be high. For this infectious pathology, there is no specific proven treatment available till date.